Ongoing pregnancy was comparable between low and normal antimullerian hormone with oral antiestrogen ovulation induction treatment. Decreased ongoing pregnancy but decreased multi-fetal gestations was observed with gonadotropin treatment for low antimullerian hormone patients.

Semen parameters are critical for couples undergoing ovulation induction/intrauterine insemination, whereas only low morphology was important to live birth after in vitro fertilization, providing evidence about which parameters are the most relevant in which settings.

Compared to the standard human chorionic gonadotropin dose, triggering with 1,500 IU human chorionic gonadotropin plus 450 IU follicle-stimulating hormone produced noninferior oocyte competence in in vitro fertilization.

COVID-19 does not seem to have any short-term effects on male fertility in patients with mild symptoms. SARS-CoV-2 was not detected in semen of recovered and COVID-19 acute infected men.

Expression of SARS-CoV-2 infection-related genes in the endometrium show different risks of infection de- pending on menstrual cycle phases, women’s age, and viral cell entry mechanisms.

After fresh in vitro fertilization with embryo transfer, the risk of small for gestational age infants was increased twofold in women with endometrial thickness ≤7.5 mm compared with >12 mm.

Conception through in vitro fertilization–intracytoplasmic sperm injection, especially using cryopreserved embryos, was associated with higher infant mortality in singleton children, predominantly during the first week of life.

There are remarkable differences in the oocyte fatty acid profile by body weight. Women who are obese or overweight have lower amounts of n-3 fatty acid.

Couples randomized to a nutrient-rich diet had higher blood levels of eicosapentaenoic acid, docosahexaenoic acid, and vitamin D, and their embryos showed altered morphokinetic markers of development.

Endometrial scratching in the luteal phase preceding ovarian stimulation significantly enhances the clinical pregnancy rate in women with three or more prior implantation failures.

ASTEROID 1 (phase 2b) supports the efficacy and safety of vilaprisan for treatment of uterine fibroids, and 2.0 mg vilaprisan is the selected dose.

Intrauterine application of auto-cross-linked hyaluronic acid after dilatation and curettage for miscarriage in women who have experienced at least one previous D&C may have a favorable effect on reproductive performance.

Medical comorbidities are associated with impaired sperm production, and the treatment of comorbidities is beneficial for not only for general health status but also for spermatogenesis restoration.